-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRM in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GRM in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GRM in Inflammation Drug Details: The drug candidate is under development for...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
Arthralgia (Joint Pain) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Arthralgia Clinical Trial Report Overview A total of 713 Arthralgia clinical trials were conducted as of March 2024. The Arthralgia clinical trial report provides a comprehensive understanding of the Arthralgia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       Europe ·       Asia-Pacific ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Extranodal Marginal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NOP Peripheral in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NOP Peripheral in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NOP Peripheral in Pain Drug Details: Small molecule is under development for...
-
Product Insights
NewPostherpetic Neuralgia – Drugs In Development, 2024
Empower your strategies with our Postherpetic Neuralgia – Drugs In Development, 2024 report and make more profitable business decisions. Postherpetic neuralgia (PHN) emerges as the predominant long-term consequence of varicella-zoster virus (VZV) reactivation, commonly known as herpes zoster or shingles. VZV, responsible for childhood varicella (chickenpox), historically affected the majority of American adults before widespread vaccination. While future generations may experience lower rates of herpes zoster and PHN, the latter remains clinically significant. PHN diagnosis heavily relies on history and physical...
-
Product Insights
NewChemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent. The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...